Retatrutide 12mg

What is Retatrutide (12 mg)?

Retatrutide (12 mg) is a synthetic peptide designed for laboratory research on metabolic regulation and hormone receptor signaling. This long-chain peptide functions as a triple receptor agonist, targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors in experimental systems.

The multi-receptor design of Retatrutide allows researchers to investigate how the coordinated activation of incretin and glucagon pathways influences metabolic signaling networks. It is commonly used in controlled laboratory and preclinical studies to explore glucose metabolism, lipid regulation, hormonal feedback mechanisms, and energy balance.

The 12 mg format provides flexibility for large-scale experiments, receptor-binding assays, and extended signaling studies. All applications are strictly for research purposes and not intended for diagnostic or therapeutic use.

Product Specifications

• CAS Number: 2381089-83-2
• Synonyms: Retatrutide acetate, LY3437943
• Peptide Sequence:
  Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight:  4845.444 g/mol
• Subcategory: Weight Loss & Metabolic Peptides
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 12 mg lyophilized powder in sealed research-grade vial
• Storage Conditions: Store at 2–8 °C (≤–20 °C for periods of non-use). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Retatrutide (12 mg)

• Triple Receptor Targeting: Designed for experimental activation of GLP-1, GIP, and glucagon receptors.
• Stability-Enhanced Structure: Incorporates amino acid substitutions (e.g., Aib residues) that improve structural stability in research systems.
• Long Peptide Chain: High molecular weight supports investigation of prolonged receptor interaction and downstream signaling effects.
• High Analytical Purity: Typically ≥95%, confirmed via chromatographic and spectrometric analysis.
• Lyophilized Presentation: Freeze-dried format supports structural integrity and controlled reconstitution.
• Research-Grade Manufacturing: Produced under controlled conditions to support reproducibility across laboratory studies.

How Retatrutide (12 mg) Supports Research

Retatrutide (12 mg) is utilized in research to explore the effects of simultaneous activation of multiple receptors on metabolic and cellular signaling. By stimulating the GLP-1 and GIP pathways, as well as glucagon receptors, Retatrutide enables the study of integrated metabolic responses rather than isolated receptor activities.
In experimental settings, it supports research into:

• Hormone-mediated regulation of glucose uptake
• Cellular energy utilization pathways
• Lipid metabolism and signaling networks
• Receptor cross-talk and intracellular signaling cascades

Its multi-agonist nature makes it ideal for studying complex endocrine feedback mechanisms and systems-level metabolic regulation.

Research Applications & Usage Information

Retatrutide (12 mg) is widely used in laboratory research, including:

• GLP-1 receptor signaling assays
• GIP receptor pathway evaluations
• Glucagon receptor activation studies
• Endocrine and metabolic pathway modeling
• Comparative research on multi-receptor agonists
• Cellular second-messenger signaling analysis
• Preclinical metabolic research models

All research involving Retatrutide is strictly confined to controlled in vitro or preclinical laboratory environments.

Handling and Storage Recommendations

• Store unopened vials at 2–8 °C. For extended preservation, maintain at ≤–20 °C.. Protect from light.
• Keep vials sealed until reconstitution.
• Minimize exposure to moisture and light.
• Allow vials to equilibrate before opening to prevent condensation.
• After reconstitution, store solutions at 2–8 °C per laboratory protocol.
• Avoid repeated freeze-thaw cycles to maintain peptide stability.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
4. Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025;87(1):159-169. doi:10.1007/s12020-024-03998-8